Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial

Trial Profile

An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions; Expanded access; Registrational
  • Sponsors Bayer
  • Most Recent Events

    • 05 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Jul 2014 New source identified and integrated (European Clinical Trials Database - EudraCT2012-002104-40).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top